A Clinical Study on the Efficacy of Udumbaradi Granules in the Management of Shayyamutrata
DOI:
https://doi.org/10.47070/ayushdhara.v13i4.2963Keywords:
Shayyamutrata, Enuresis, Bed-Wetting, Udumbaradi GranulesAbstract
Shayyamutrata (Nocturnal Enuresis) is a psychosomatic pediatric disorder whose sole manifestation is involuntary bed-wetting during sleep. Though not physically harmful, it carries significant psychological burden for the child and social embarrassment for parents. Classical Ayurvedic texts describe the condition only briefly, with treatment guidelines remaining sparse. The predominant Strotas involved are Mutravaha and Manovaha, while Vata and Kapha Dosha, along with Tama, form the core of its etiopathogenesis. Given its multifactorial, mind-body nature, management requires a multidimensional approach. This single-arm clinical study was undertaken to evaluate the efficacy of Udumbaradi Granules- comprising Udumbara, Ashwagandha, Ashwattha, Mandukparni, Amalaki, and Vidanga-in the management of Shayyamutrata. Of 41 children initially enrolled, 35 patients aged 3 to 12 years, of both sexes, with a confirmed diagnosis of bedwetting, completed the 15-day trial after satisfying inclusion and exclusion criteria. Patients were assessed on the 7th and 15th day for change in the frequency and occurrence of bedwetting. Following treatment, the frequency of bedwetting reduced by 61.54% and its occurrence by 37.65%, both changes being statistically significant (Chi-square 57.211 and 33.522 respectively, p<0.05). No adverse drug reactions were observed during the study period. These findings indicate that Udumbaradi Granules are a safe and effective Ayurvedic therapeutic option for Shayyamutrata, acting by alleviating Vata and clearing Kapha-induced Avarana, thereby strengthening bladder control. Larger, multi-centric trials with extended follow-up are recommended to substantiate these results.
Downloads
Downloads
Published
Issue
Section
License
Copyright (c) 2026 AYUSHDHARA

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
